Lund University Bioscience AB has decided to distribute its shares in Follicum AB
Follicum AB (”Follicum”) announce that Lund University Bioscience AB (LU Bio) has had an extraordinary general meeting 31 January, 2018. It was decided that the company’s shares in Follicum, will be distributed to its LU Bio’s shareholders. The distribution is planned to occur during week 6, 2018. LU Bio has 2 320 370 shares in Follicum, divided on approx. 30 shareholders. Several of these are existing shareholders in Follicum. LU Bio’s largest owners are Stiftelsen Akademihemman (11,02 %), LU Holding AB (10,02%), Kudu AB (10,0%), LMK Forward AB (9,11%) and Östersjöstiftelsen (7,94%).
“LU Bio is a consortium of investors who has supported Follicum from its foundation, during its early development until the position the company has today,” says Lars Bruzelius, chairman of the board in LU Bio and board member in Follicum. ”This task has now been finalized in a successful way and it is with great pleasure the shares can now be distributed to our investors”.
“The support from LU Bio has been instrumental in the development of Follicum. Moving forward, a direct ownership by its investors is important to Follicum”, says Jan Alenfall, CEO Follicum. “We are grateful for LU Bio’s contribution. We look forward to continue the development of our projects towards positive clinical phase II data together with existing and new investors”.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
Email: info@follicum.com
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 1st of February 2018.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com
Tags: